Peter Lawson
Stock Analyst at Barclays
(1.99)
# 3,123
Out of 5,139 analysts
100
Total ratings
42.53%
Success rate
-9.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $20.52 | +7.21% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $106.21 | -4.91% | 1 | Oct 29, 2025 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $338.19 | +13.84% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $35.84 | +11.61% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $16.79 | +48.90% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $7.04 | -57.39% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $43.96 | -9.01% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.72 | +74.42% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.19 | +68.07% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $6.31 | +58.48% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.36 | +69.49% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.79 | -53.09% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $33.35 | +55.92% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $8.46 | +30.02% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $12.20 | +31.15% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $6.51 | +130.41% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $21.80 | -35.78% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.41 | +112.77% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.13 | +165.49% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.31 | +205.34% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $120.28 | -50.12% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $7.35 | +131.29% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $19.21 | +61.37% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $13.01 | -0.08% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.81 | +176.24% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $5.39 | -35.06% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $141.65 | +157.68% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.19 | +69.18% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $37.68 | +1,094.27% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.03 | +2,116.75% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $53.51 | -15.90% | 2 | Jan 23, 2018 |
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $20.52
Upside: +7.21%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $106.21
Upside: -4.91%
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $338.19
Upside: +13.84%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $35.84
Upside: +11.61%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $16.79
Upside: +48.90%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $7.04
Upside: -57.39%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $43.96
Upside: -9.01%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.72
Upside: +74.42%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.19
Upside: +68.07%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $6.31
Upside: +58.48%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.36
Upside: +69.49%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.79
Upside: -53.09%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $33.35
Upside: +55.92%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $8.46
Upside: +30.02%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $12.20
Upside: +31.15%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $6.51
Upside: +130.41%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $21.80
Upside: -35.78%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.41
Upside: +112.77%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.13
Upside: +165.49%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.31
Upside: +205.34%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $120.28
Upside: -50.12%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $7.35
Upside: +131.29%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $19.21
Upside: +61.37%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $13.01
Upside: -0.08%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.81
Upside: +176.24%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $5.39
Upside: -35.06%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $141.65
Upside: +157.68%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.19
Upside: +69.18%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $37.68
Upside: +1,094.27%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.03
Upside: +2,116.75%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $53.51
Upside: -15.90%